Kai H. Thng

Singapore, Singapore

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

The functional imperative in high-grade glioma.

The functional imperative in high-grade glioma.

Journal: Experimental & molecular medicine

Published: June 09, 2025

The role of histone demethylase PHF2 as a tumour suppressor in hepatocellular carcinoma by regulating SRXN1.

The role of histone demethylase PHF2 as a tumour suppressor in hepatocellular carcinoma by regulating SRXN1.

Journal: Oncogenesis

Published: May 20, 2025

Artificial intelligence for breast cancer management.

Artificial intelligence for breast cancer management.

Journal: Communications medicine

Published: April 24, 2025

Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review.

Mechanistic insights and the clinical prospects of targeted therapies for glioblastoma: a comprehensive review.

Journal: Experimental hematology & oncology

Published: December 30, 2023

A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids.

A functional personalised oncology approach against metastatic colorectal cancer in matched patient derived organoids.

Journal: NPJ precision oncology

Published: November 16, 2023

Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol.

Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol.

Journal: PloS one

Published: October 26, 2023

NanoBeacon.AI: AI-Enhanced Nanodiamond Biosensor for Automated Sensitivity Prediction to Oxidative Phosphorylation Inhibitors.

NanoBeacon.AI: AI-Enhanced Nanodiamond Biosensor for Automated Sensitivity Prediction to Oxidative Phosphorylation Inhibitors.

Journal: ACS sensors

Published: May 02, 2023

Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer.

Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer.

Journal: Molecular oncology

Published: October 03, 2022

Splice-switch oligonucleotide-based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC-driven hepatocellular carcinoma.

Splice-switch oligonucleotide-based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC-driven hepatocellular carcinoma.

Journal: Bioengineering & translational medicine

Published: April 19, 2022

Enhanced penetrative siRNA delivery by a nanodiamond drug delivery platform against hepatocellular carcinoma 3D models.

Enhanced penetrative siRNA delivery by a nanodiamond drug delivery platform against hepatocellular carcinoma 3D models.

Journal: Nanoscale

Published: September 20, 2021

Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age.

Capitalizing on Synthetic Lethality of MYC to Treat Cancer in the Digital Age.

Journal: Trends in pharmacological sciences

Published: August 05, 2020

Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression.

Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression.

Journal: Hepatology communications

Published: April 22, 2020

Showing 1-12 of 12

Last Updated: 09/26/2026